Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Growth and metastatic behavior of molecularly well-characterized human breast cancer cell lines in mice.

Riaz M, Setyono-Han B, Timmermans MA, Trapman AM, Bolt-de Vries J, Hollestelle A, Janssens RC, Look MP, Schutte M, Foekens JA, Martens JW.

Breast Cancer Res Treat. 2014 Nov;148(1):19-31. doi: 10.1007/s10549-014-3142-0. Epub 2014 Sep 30.

PMID:
25266129
2.

Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.

Sieuwerts AM, Look MP, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, de Weerd V, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3319-28.

3.

How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study.

Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA.

Clin Cancer Res. 2005 Oct 15;11(20):7311-21.

4.

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

Foekens JA, Portengen H, van Putten WL, Trapman AM, Reubi JC, Alexieva-Figusch J, Klijn JG.

Cancer Res. 1989 Dec 15;49(24 Pt 1):7002-9.

Supplemental Content

Loading ...
Support Center